LCZ 696在心血管疾病治疗中的研究进展

Abstract
Figure/Table
References (33)
Related Citation (15)

Download: PDF (0 KB) HTML (43 KB)
Export: BibTeX | EndNote (RIS)

Abstract Cardiovascular disease has become one of the serious diseases threatening human health.Although various drugs have been used for cardiovascular diseases,the morbidity and mortality are still high.Therefore,exploring new medicines is a hot spot in the treatment of cardiovascular diseases now.LCZ 696 is a novel neuroendocrine inhibitor with a dual inhibition of angiotensin receptor and nekephalin,and it is a cardiovascular drug with a new mechanism of action,which is considered to be one of the most important advances in the field of cardiovascular disease treatment in the past 10 years.This paper reviews the mechanism of action,the pharmacokinetics of LCZ 696 and the researches in the treatment of cardiovascular diseases.

Key words： LCZ 696 Heart failure Hypertension Myocardial infarction

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	CHENG Zhao
	JIA Da-lin

Cite this article:

CHENG Zhao,JIA Da-lin. Research progress of LCZ 696 in the treatment of cardiovascular disease[J]. 中国当代医药, 2019, 26(2): 29-33.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2019/V26/I2/29

[6]	Daniels LB，Maisel AS.Natriuretic peptides[J].J Am Coll Cardiol，2007，50（25）：2357-2368.
[8]	匡泽民，王瑛，王佳洁，等.血管紧张素受体-脑啡肽酶抑制剂 LCZ969[J].中国新药杂志，2016，25（21）：2414-2420.
[1]	Roth G，Johnson C，Abajobir A，et al.Global，regional，and national burden of cardiovascular diseases for 10 causes，1990 to 2015[J].J Am Coll Cardiol，2017，70（1）：1-25.
[2]	Mozaffarian D，Benjamin EJ，Go AS，et al.Heart disease and stroke statistics-2016 update：a report from the American Heart Association[J].Circulation，2016，133（4）：e38-e360.
[3]	Volpe M，Tocci G，Battistoni A，et al.Angiotensin II receptor blockerneprilysininhibitor（ARNI）：newavenuesincardiovascular therapy[J].High Blood Press Cardiovasc Prev，2015，22（3）：241-246.
[4]	Gu J，Noe A，Chandra P，et al.Pharmacokinetics and pharmacodynamics of LCZ696，a novel dual acting angiotensin receptor-neprilysin inhibitor （ARNI）[J].J Clin Pharmacol，2010，50（4）：401-414.
[5]	Mangiafico S，Boerrigter LC，Andersen IA，et al.Neutral endopeptidase inhibitor and the natriuretic peptide system：an evolving strategy in cardiovascular therapeuretic[J].Eur Heart J，2003，34（12）：886-893.
[7]	Nakagawa H，Oberwinkler H，Nikolaev VO，et al.Atrial natriuretic peptide locally counteracts the deleterious effects of cardiomyocyte mineralocorticoid receptor activation[J].Circ Heart Fail，2014，7（5）：814-821.
[9]	Reed BN，Street SE，Jensen SC.Time and technology will tell：the pathophysiologic basic of neurohormonal modulation in heart failure[J].Heart Fail Clin，2014，10（4）：543-557.
[10]	Mcmurray JJ.Neprilysin inhibition to treat heart failure：a taleofscience，serendipity，andsecondchances[J].EurJHeart Fail，2015，17（3）：242-247.
[11]	Mcmurray JJ，Packer M，Desai AS，et al.Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotension-coverting enzyme inhibition in patients with chronic systolic heart failure：rational for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trail （PARADIGM-HF）[J].Eur J Heart Fail，2013，15（9）：1062-1073.
[12]	Suematsu Y，Jing W，Nunes A，et al.LCZ696 （Sacubitril/Valsartan），an angiotensin-receptor neprilysin inhibitor，attenuates cardiac hypertrophy，fibrosis，and vasculopathy in a rat model of chronic kidney disease[J].J Caed Fail，2018，24（4）:266-275.
[13]	Kraigher-krainer E，Shah AM，Gupta DK，et all.Impaired systolic function by strain imaging in heart failure with preserved ejection fraction[J].J Am Coll Cardiol，2014，63（5）：447-456.
[14]	邱爽，杨波，平海芹，等.血管紧张素受体脑啡肽酶抑制剂在心力衰竭中的研究进展[J].中国循环杂志，2015，30（11）：1131-1133.
[15]	Pardeep SJ，Brain C，Milton P，et al.Independence of the blood pressure lowing effect and efficacy of the angiotensin receptor neprilysin，LCZ696，in patients with heart failure with preserved ejection fraction：an analysis of the PARA MOUNT trial[J].Eur J Heart Fail，2014，16：671-677.
[16]	Aurigemma GP，Gaasch WH.Diastolic heart failure[J].N Engl J Med，2004，351（11）：1097-1105.
[17]	Borlaug B，Paulus WJ.Heart failure with preserved ejection fraction：pathophysiology，diagnosis，andtreatment[J].EurHeart J，2011，32（6）：670-679.
[18]	Solomon SD，Zile M，Pieske B，et al.The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction：a phase 2 double-blind randomised controlled trial[J].Lancet，2012，380（9851）：1387-1395.
[19]	Simpson J，Jhund PS，Silva Cardoso J，et al.Comparing LCZ696 with enalapril according to baseline risk using the MAGGIC and EMPHASIS-HF risk scores：an analysis of mortality and morbidity in PARADIGM-HF[J].J Am Coll Cardiol，2015，66（19）：2059-2071.
[20]	Pocock SJ，Ariti CA，McMurray JJV，et al.Predicting survival in heart failure：a risk score based on 39372 patients from 30 studies[J].Eur Heart J，2013，34（19）：1404-1413.
[21]	Yancy CW，Jessup M，Bozkurt B，et al.2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure：a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the Heart Failure Society of America[J].Circulation，2017，136（6）：e137-e161.
[22]	Ulrik MM，Jianjian G，Pardeep SJ，et al.Effect of sacubitril/valsartan on recurrent events in the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial（PARADIGMHF）[J].Eur Heart J，2018，20（4）：760-768.
[23]	McMurray JJ.Consensus to EMPHASIS：the overwhelming evidence which makes blockade of the renin-angiotensinaldosterone system the cornerstone of therapy for systolic heart failure[J].Eur J Heart Fai，2011，13（9）：929-936.
[24]	McMurray JJ，Packer M，Desai AS，etal.Angiotensinneprilysin inhibition versus enalapril in heart failure[J].N Engl J Med，2014，371（11）：993-1004.
[25]	Kristensen SL，Martinez F，Jhund PS，et al.Geographic variations in the PARADIGM-HF heart failure trial[J].Eur Heart J，2016，37（41）：3167-3174.
[26]	Simpson J，Jhund PS，Rouleau J，et al.Effect of sacubitril/valsartan compared with enalapril，according to etiology in PARADIGM-HF[J].J Am Coll Cardiol，2017，69（11）：919-920.
[27]	Ruilope LM，Dukat A，Bohm M，et al.Blood-pressure reduction with LCZ696，a novel dual-acting inhibitor of the angiotensinⅡreceptor and neprilysin：a randomised，double-blind，placoebo controlled，active comparator study[J].Lancet，2010，375（9722）：1255-1266.
[28]	KarioK，SunN，Chiang FT，etal.Efficacyandsafety of LCZ696，a first-in-class angiotensin receptor neprilysin inhibitor，in Asian patients with hypertension：a randomized，doubleblind，placebo controlled study[J].Hypertension，2014，63（4）：698-705.
[29]	Tzung-Dau W，Ru-San T，Hae-Young L，et al.Effects of Sacubitril/Valsartan （LCZ696） onnatriuresis，diuresis，blood pressures，and NT-proBNP in Salt-Sensitive hypertension[J].Hypertension，2017，69（1）：32-41.
[30]	Ji-Guang W，Kimihiko Y，Antonio SJ，et al.Efficacy and safety of sacubitril/valsartan （LCZ696） add-on to amlodipine in Asian patients with systolic hypertension uncontrolled with amlodipine monotherapy[J].J Hyperten，2017，35（4）：877-885.
[31]	Andrew RK，Jiayu L，Thomas JW，et al.Angiotensin receptor neprilysin inhibition provides superior cardioprotection compared to angiotensin converting enzyme inhibition after experimental myocardial infarction[J].Int J Cardiol，2018，258：192-198.
[32]	Ishii M，Kaikita K， Sato K，et al.Cardioprotective Effects of LCZ696 （Sacubitril/Valsartan）After Experimental Acute Myocardial Infarction[J].JACC Basic Trans Sci，2017，2（6）：655-668.
[33]	Fala L.Entresto （sacubitril/valsartan）：first-in-class angiotensin receptor neprilysin inhibitor FDA approved for patients with heart failure[J].Am Health Drug Benefits，2015，8（6）：330-334.